Chronotherapy with low-dose modified-release prednisone for the management of rheumatoid arthritis: a review

References

• ShettyAHansonRKorstenPTocilizumab in the treatment of rheumatoid arthritis and beyondDrug Des Devel Ther20148349364
   PubMed Web of Science ®Google Scholar
• ZampeliEVlachoyiannopoulosPGTzioufasAGTreatment of rheumatoid arthritis: unraveling the conundrumJ Autoimmun20156511826515757
   PubMed Web of Science ®Google Scholar
• BackmanCLEmployment and work disability in rheumatoid arthritisCurr Opin Rheumatol200416214815214770102
   PubMed Web of Science ®Google Scholar
• SokkaTWork disability in early rheumatoid arthritisClin Exp Rheumatol2003215 Suppl 31S71S7414969054
   PubMed Web of Science ®Google Scholar
• KojimaMKojimaTIshiguroNPsychosocial factors, disease status, and quality of life in patients with rheumatoid arthritisJ Psychosom Res200967542543119837205
   PubMed Web of Science ®Google Scholar
• CutoloMKitasGDvan RielPLBurden of disease in treated rheumatoid arthritis patients: going beyond the jointSemin Arthritis Rheum201443447948824080116
   PubMed Web of Science ®Google Scholar
• da SilvaJAPhillipsSButtgereitFImpact of impaired morning function on the lives and well-being of patients with rheumatoid arthritisScand J Rheumatol Suppl201112561121529304
   PubMedGoogle Scholar
• YaziciYPincusTKautiainenHSokkaTMorning stiffness in patients with early rheumatoid arthritis is associated more strongly with functional disability than with joint swelling and erythrocyte sedimentation rateJ Rheumatol20043191723172615338490
   PubMed Web of Science ®Google Scholar
• WesthoffGButtgereitFGromnica-IhleEZinkAMorning stiffness and its influence on early retirement in patients with recent onset rheumatoid arthritisRheumatology (Oxford)200847798098418413345
   PubMed Web of Science ®Google Scholar
• MattilaKButtgereitFTuominenRImpact of morning stiffness on working behaviour and performance in people with rheumatoid arthritisRheumatol Int201434121751175824871158
   PubMed Web of Science ®Google Scholar
• MattilaKButtgereitFTuominenRInfluence of rheumatoid arthritis-related morning stiffness on productivity at work: results from a survey in 11 European countriesRheumatol Int201535111791179726007151
   PubMed Web of Science ®Google Scholar
• KowankoICPownallRKnappMSSwannellAJMahoneyPGCircadian variations in the signs and symptoms of rheumatoid arthritis and in the therapeutic effectiveness of flurbiprofen at different times of dayBr J Clin Pharmacol19811154774847272159
   PubMed Web of Science ®Google Scholar
• HarknessJARichterMBPanayiGSCircadian variation in disease activity in rheumatoid arthritisBr Med J Clin Res Ed19822846315551554
   PubMed Web of Science ®Google Scholar
• BellamyNSothernRBCampbellJBuchananWWCircadian rhythm in pain, stiffness, and manual dexterity in rheumatoid arthritis: relation between discomfort and disabilityAnn Rheum Dis19915042432482029206
   PubMed Web of Science ®Google Scholar
• StraubRHCutoloMCircadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic managementArthritis Rheum200756239940817265475
   PubMed Web of Science ®Google Scholar
• SpiesCMStraubRHCutoloMButtgereitFCircadian rhythms in rheumatology – a glucocorticoid perspectiveArthritis Res Ther201416Suppl 2S325608777
   PubMed Web of Science ®Google Scholar
• NicolaidesNCCharmandariEChrousosGPKinoTCircadian endocrine rhythms: the hypothalamic-pituitary-adrenal axis and its actionsAnn N Y Acad Sci20141318718024890877
   PubMed Web of Science ®Google Scholar
• HenchPSPotential reversibility of rheumatoid arthritisAnn Rheum Dis194982909618623811
   PubMed Web of Science ®Google Scholar
• HenchPSKendallECThe effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritisProc Staff Meet Mayo Clin194924818119718118071
   PubMed Web of Science ®Google Scholar
• Da SilvaJABijlsmaJWOptimizing glucocorticoid therapy in rheumatoid arthritisRheum Dis Clin North Am200026485988011084948
   PubMed Web of Science ®Google Scholar
• PincusTSokkaTCutoloMThe past versus the present, 1980–2004: reduction of mean initial low-dose, long-term glucocorticoid therapy in rheumatoid arthritis from 10.3 to 3.6 mg/day, concomitant with early methotrexate, with long-term effectiveness and safety of less than 5 mg/dayNeuroimmunomodulation2015221–28910325228430
   PubMed Web of Science ®Google Scholar
• Gaujoux-VialaCNamJRamiroSEfficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritisAnn Rheum Dis201473351051524395555
   PubMed Web of Science ®Google Scholar
• PincusTCutoloMClinical trials documenting the efficacy of low-dose glucocorticoids in rheumatoid arthritisNeuroimmunomodulation2015221–2465025227901
   PubMed Web of Science ®Google Scholar
• BoersMVerhoevenACMarkusseHMRandomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritisLancet199735090743093189251634
   PubMed Web of Science ®Google Scholar
• SvenssonBBoonenAAlbertssonKvan der HeijdeDKellerCHafströmILow-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trialArthritis Rheum200552113360337016255010
   PubMed Web of Science ®Google Scholar
• WassenbergSRauRSteinfeldPZeidlerHVery low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trialArthritis Rheum200552113371338016255011
   PubMed Web of Science ®Google Scholar
• TodoertiMScirèCABoffiniNBugattiSMontecuccoCCaporaliREarly disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritisAnn N Y Acad Sci2010119313914520398020
   PubMed Web of Science ®Google Scholar
• BakkerMFJacobsJWGWelsingPMJLow-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trialAnn Intern Med2012156532933922393128
   PubMed Web of Science ®Google Scholar
• MontecuccoCTodoertiMSakellariouGScirèCACaporaliRLow-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised studyArthritis Res Ther2012143R11222584017
   PubMed Web of Science ®Google Scholar
• ArvidsonNGGudbjörnssonBLarssonAHällgrenRThe timing of glucocorticoid administration in rheumatoid arthritisAnn Rheum Dis199756127319059137
   PubMed Web of Science ®Google Scholar
• ButtgereitFDoeringGSchaefflerAEfficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trialLancet2008371960820521418207016
   PubMed Web of Science ®Google Scholar
• ButtgereitFDoeringGSchaefflerATargeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritisAnn Rheum Dis20106971275128020542963
   PubMed Web of Science ®Google Scholar
• ButtgereitFMehtaDKirwanJLow-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)Ann Rheum Dis201372220421022562974
   PubMed Web of Science ®Google Scholar
• CassidyJClarkeSDíaz-RubioERandomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancerJ Clin Oncol200826122006201218421053
   PubMed Web of Science ®Google Scholar
• AltenRDöringGCutoloMHypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisoneJ Rheumatol201037102025203120682671
   PubMed Web of Science ®Google Scholar
• AltenRGrahnAHoltRJRicePButtgereitFDelayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritisRMD Open201511e00013426535146
   PubMedGoogle Scholar
• ClarkeLLJessopDSHuntLPStraubRHPerryMGKirwanJRAlleviation of morning joint stiffness by low-dose prednisone in rheumatoid arthritis is associated with circadian changes in IL-6 and cortisolInt J Clin Rheumatol201162241249
   Google Scholar
• NaderNChrousosGPKinoTCircadian rhythm transcription factor CLOCK regulates the transcriptional activity of the glucocorticoid receptor by acetylating its hinge region lysine cluster: potential physiological implicationsFASEB J20092351572158319141540
   PubMed Web of Science ®Google Scholar
• CharmandariEChrousosGPLambrouGIPeripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in manPLoS One201169e2561221980503
   PubMed Web of Science ®Google Scholar
• AletahaDFunovitsJKeystoneECSmolenJSDisease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patientsArthritis Rheum200756103226323517907167
   PubMed Web of Science ®Google Scholar
• SchipperLGFransenJden BroederAAVan RielPLTime to achieve remission determines time to be in remissionArthritis Res Ther2010123R9720487520
   PubMed Web of Science ®Google Scholar
• BykerkVPKeystoneECKuriyaBLarchéMThorneJCHaraouiBAchieving remission in clinical practice: lessons from clinical trial dataClin Exp Rheumatol201331462163223622099
   PubMed Web of Science ®Google Scholar
• MontiSMontecuccoCBugattiSCaporaliRRheumatoid arthritis treatment: the earlier the better to prevent joint damageRMD Open20151Suppl 1e00005726557378
   PubMedGoogle Scholar
• AletahaDAlastiFSmolenJSOptimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time pointAnn Rheum Dis20167581479148526420577
   PubMed Web of Science ®Google Scholar
• SmolenJSAletahaDBijlsmaJWTreating rheumatoid arthritis to target: recommendations of an international task forceAnn Rheum Dis201069463163720215140
   PubMed Web of Science ®Google Scholar
• SmolenJSBreedveldFCBurmesterGRTreating rheumatoid arthritis to target: 2014 update of the recommendations of an international task forceAnn Rheum Dis201675131525969430
   PubMed Web of Science ®Google Scholar
• GallowayJBHyrichKLMercerLKAnti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderlyRheumatology (Oxford)201150112413120675706
   PubMed Web of Science ®Google Scholar
• MarchesoniAZaccaraEGorlaRTNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practiceAnn N Y Acad Sci2009117383784619758236
   PubMed Web of Science ®Google Scholar
• HansenMPodenphantJFlorescuAA randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effectsAnn Rheum Dis1999581171371810531077
   PubMed Web of Science ®Google Scholar
• LandewéRBMBoersMVerhoevenACCOBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief interventionArthritis Rheum200246234735611840436
   PubMed Web of Science ®Google Scholar
• MaillefertJFCombeBGoupillePCantagrelADougadosMLong term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled studyAnn Rheum Dis200362876476612860733
   PubMed Web of Science ®Google Scholar
• VerschuerenPEsselensGWesthovensRDaily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritisRheumatology (Oxford)2008471596418039681
   PubMed Web of Science ®Google Scholar
• den UylDter WeeMBoersMA non-inferiority trial of an attenuated combination strategy (‘COBRA-light’) compared to the original COBRA strategy: clinical results after 26 weeksAnn Rheum Dis20147361071107823606682
   PubMed Web of Science ®Google Scholar
• VerschuerenPDe CockDCorluyLMethotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trialAnn Rheum Dis2015741273425359382
   PubMed Web of Science ®Google Scholar
• VerschuerenPDe CockDCorluyLPatients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trialArthritis Res Ther2015179725889222
   PubMed Web of Science ®Google Scholar
• KirwanJRThe effect of glucocorticoids on joint destruction in rheumatoid arthritis. The arthritis and rheumatism council low-dose glucocorticoid study groupN Engl J Med199533331421467791815
   PubMed Web of Science ®Google Scholar
• van EverdingenAAJacobsJWSiewertsz Van ReesemaDRBijlsmaJWLow-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trialAnn Intern Med20021361112
   PubMed Web of Science ®Google Scholar
• HicklingPJacobyRKKirwanJRJoint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and rheumatism council low dose glucocorticoid study groupBr J Rheumatol19983799309369783756
   PubMedGoogle Scholar
• SmolenJSLandewéRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateAnn Rheum Dis201473349250924161836
   PubMed Web of Science ®Google Scholar
• BijlsmaJWDisease control with glucocorticoid therapy in rheumatoid arthritisRheumatology (Oxford)201251Suppl 4iv9iv1322685274
   PubMed Web of Science ®Google Scholar
• CroffordLJKalogerasKTMastorakosGCircadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritisJ Clin Endocrinol Metab1997824127912839100607
   PubMed Web of Science ®Google Scholar
• PerryMGKirwanJRJessopDSHuntLPOvernight variations in cortisol, interleukin 6, tumour necrosis factor alpha and other cytokines in people with rheumatoid arthritisAnn Rheum Dis2009681636818375536
   PubMed Web of Science ®Google Scholar
• KirwanJRClarkeLHuntLPPerryMGStraubRHJessopDSEffect of novel therapeutic glucocorticoids on circadian rhythms of hormones and cytokines in rheumatoid arthritisAnn N Y Acad Sci2010119312713320398018
   PubMed Web of Science ®Google Scholar
• Prevalence of Morning Stiffness in a US Registry Population of Rheumatoid Arthritis PatientsACR Meet Abstr Available from: http://acrabstracts.org/abstract/prevalence-of-morning-stiffness-in-a-us-registry-population-of-rheumatoid-arthritis-patients/Accessed February 12, 2016
   Google Scholar
• DerendorfHRuebsamenKClarkeLSchaefflerAKirwanJRPharmacokinetics of modified-release prednisone tablets in healthy subjects and patients with rheumatoid arthritisJ Clin Pharmacol201353332633323444285
   PubMed Web of Science ®Google Scholar
• PfeifferBMKrenzerSDockhornRImpact of modified-release prednisone on functional ability in patients with rheumatoid arthritisRheumatol Int20133361447145423179262
   PubMed Web of Science ®Google Scholar
• AltenRHoltRGrahnAMorning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisoneScand J Rheumatol201544535435826114379
   PubMed Web of Science ®Google Scholar
• CharmandariENicolaidesNCChrousosGPAdrenal insufficiencyLancet201438399352152216724503135
   PubMed Web of Science ®Google Scholar
• WoodsCPArgeseNChapmanMAdrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisolEur J Endocrinol2015173563364226294794
   PubMed Web of Science ®Google Scholar
• KirwanJRHickeySHHällgrenRThe effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritisArthritis Rheum20065451415142116645969
   PubMed Web of Science ®Google Scholar
• RadikovaZRovenskyJVlcekMAdrenocortical response to low-dose ACTH test in female patients with rheumatoid arthritisAnn N Y Acad Sci2008114856256619120158
   PubMed Web of Science ®Google Scholar
• StrehlCButtgereitFOptimized glucocorticoid therapy: teaching old drugs new tricksMol Cell Endocrinol20133801–2324023403055
   PubMed Web of Science ®Google Scholar
• KavanaughAWellsAFBenefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritisRheumatology (Oxford)201453101742175124729402
   PubMed Web of Science ®Google Scholar
• van der GoesMCJacobsJWBijlsmaJWThe value of glucocorticoid co-therapy in different rheumatic diseases – positive and adverse effectsArthritis Res Ther201416Suppl 2S225608693
   PubMed Web of Science ®Google Scholar
• AltenRWiebeEHypothalamic-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with different glucocorticoid approachesNeuroimmunomodulation2015221–2838825228310
   PubMed Web of Science ®Google Scholar
• SantiagoTJacobsJWSaagKGButtgereitFPereira da SilvaJABalancing the benefits and risks of low-dose glucocorticoid in rheumatoid arthritisActa Reumatol Port2015401102225844966
   PubMed Web of Science ®Google Scholar
• HuscherDThieleKGromnica-IhleEDose-related patterns of glucocorticoid-induced side effectsAnn Rheum Dis20096871119112418684744
   PubMed Web of Science ®Google Scholar
• SantiagoTda SilvaJASafety of glucocorticoids in rheumatoid arthritis: evidence from recent clinical trialsNeuroimmunomodulation2015221–2576525228045
   PubMed Web of Science ®Google Scholar
• PenesováARádikováZVlčekMChronic inflammation and low-dose glucocorticoid effects on glucose metabolism in premenopausal females with rheumatoid arthritis free of conventional metabolic risk factorsPhysiol Res2013621758323173679
   PubMed Web of Science ®Google Scholar
• ButtgereitFSpiesCMBijlsmaJWNovel glucocorticoids: where are we now and where do we want to go?Clin Exp Rheumatol2015334 Suppl 92S29S3326457359
   PubMed Web of Science ®Google Scholar
• AltenRChronotherapy with modified-release prednisone in patients with rheumatoid arthritisExpert Rev Clin Immunol20128212313322288450
   PubMed Web of Science ®Google Scholar
• ButtgereitFSzechinskiJDoeringGIntegrated safety summary of modified-release prednisone and immediate-release prednisone comparing doses <5mg/day versus >5mg/dayArthritis and Rheumatism2011631S475
   Google Scholar